Objective:
The adolescent/adult pivotal phase 3 pathfinder 2 trial assessed N8-GP (turoctocog alfa pegol, ESPEROCT®) use for routine prophylaxis and treatment of bleeds in previously treated patients (PTPs).
Methods:…
FOR IMMEDIATE RELEASE
Media Contact
Ilana Ostrin
iostrin@hemophilia.org
212-328-3769
Today, the United States Supreme Court (SCOTUS) released a decision in California v. Texas, the most recent lawsuit concerning the…
A new article, “Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia,” was published in the Journal of Clinical Medicine (JCM).
In this review, the authors discuss some of the…
A new paper published in The Journal of Haemophilia Practice advances the concept of shared decision making (SDM) between the hemophilia patient and their healthcare provider (HCP).
As a relatively new approach to care, SDM sheds the one-size-…
In the US, a rare disease or disorder is defined as one that affects fewer than 200,000 people. This means hemophilia A and B, and the less-common factor deficiencies such as I, II, V, VII, X, XI, XII and XIII, are all rare disorders.The National…
Representation of Gender in Research and Clinical Contexts
Speaker(s): Alexis Dinno, MPH; Michael Recht, MD
Did you miss the July 7th Wednesday Webinar? If so click here to listen to Alexis Dinno, MPH; Michael Recht, MD…
COVID Vaccines
Speaker(s): Karen Remley, MD, MBA, MPH
Did you miss the July 14th Wednesday Webinar? If so, click here to listen to Karen Remley, MD, MBA, MPH discuss COVID vaccine implementation.
Register for…
Artificial Intelligence/Machine Learning Research in Hemophilia
Speaker(s): Moses Miles; Michael Recht, MD, Crystal Watson
Did you miss the July 21st Wednesday Webinar series? If so click here to listen to Moses Miles and…
Ensuring Health Equity with Emerging Therapies
Speaker(s): Leonard Valentino, MD
Did you miss the July 28th Wednesday Webinar? If so click here to listen to NHF President and CEO Dr. Len Valentino discuss ensuring health…